biolabs-heidelberg
Boehringer Ingelheim supports the launch of BioLabs first European Location in Heidelberg.
Search
Collaboration to fight NCDs
70 percent of global deaths are attributable to NCDs and severely impacting on people in low- and middle-income countries. Help is desperately needed.
“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
EMPERIAL-heart-failure-toplineresults
Update on the EMPERIAL-Reduced and EMPERIAL-Preserved studies, which assess exercise ability in adults with chronic heart failure with reduced and preserved ejection fraction
Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
Largest European development center for biotechnology
Boehringer Ingelheim inaugurates largest European development center for biotechnology
Boehringer Ingelheim partners with GNA Biosolutions
Boehringer Ingelheim partners with GNA Biosolutions to develop African swine fever diagnostic test.
Solid Fundations | Bioxcellence | Boehringer Ingelheim
Discover BioXcellence's innovative biopharmaceutical contract manufacturing services, built on a proven track record & solid foundation. Explore now!
H5N1: Bird flu again. What’s different now?
H5N1: how is avian influenza now? The virus known for affecting wild & domestic birds has been detected in dairy cows in the US. What you need to know.
A tool to aid in the prevention of African swine fever
ASF COMBAT is an online management and biosecurity assessment tool aimed at reducing the African swine fever introduction risk level.
SPEVIGO®
SPEVIGO® (spesolimab) is a novel, humanized, selective antibody for the treatment of generalized pustular psoriasis (GPP) flares.
Spiriva®
Maintenance treatment of patients with COPD (including chronic bronchitis and emphysema), maintenance treatment of associated dyspnoea and for prevention of exacerbations.
Spiriva® Respimat®
An add-on maintenance treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids.
Striverdi® Respimat®
Maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Aggrenox®
Prevention of stroke following an initial first stroke, or transient ischaemic attacks (TIA).
Metalyse®
Fibrinolytic treatment of acute myocardial infarction. Fibrinolytic treatment of acute ischaemic stroke.
Catapresan®
Treatment of hypertension.
Trajenta®
Treatment of type 2 diabetes mellitus to improve glycaemic control in adults, used in monotherapy (if metformin is not tolerated or contraindicated) or in combination therapy.
Twynsta®
Treatment of hypertension alone or with other antihypertensive agents. As initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals (USA). Add-on therapy in adult patients with not adequately co
Sifrol®
Symptomatic treatment of idiopathic Parkinson’s disease. It may be used as monotherapy or in combination with levodopa. Symptomatic treatment of idiopathic moderate to severe restless legs syndrome.
Actilyse®
Fibrinolytic treatment of acute ischaemic stroke, acute myocardial infarction, acute massive pulmonary embolism. Fibrinolytic treatment of occluded catheters.
MicardisPlus®
US: Treatment of hypertension alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Not indicated for
Berotec®
Symptomatic treatment of acute asthma attacks. Prophylaxis of exercise-induced asthma bronchiale. Symptomatic treatment of allergic and non-allergic asthma bronchiale and other conditions with reversible airway narrowing, e.g. chronic obstructive bro
Jardiance®
Treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise.
Synjardy®
Treatment of type 2 diabetes mellitus to improve glycaemic control in adults when treatment with metformin does not lead to sufficient control or when patients are treated with jardiance® (empagliflozin) and metformin.